MYE0 Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.26 |
| 52 Week High | UK£4.96 |
| 52 Week Low | UK£2.86 |
| Beta | 1.13 |
| 11 Month Change | -0.61% |
| 3 Month Change | -13.30% |
| 1 Year Change | 5.16% |
| 33 Year Change | -66.22% |
| 5 Year Change | n/a |
| Change since IPO | -55.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYE0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.4% | -1.1% | -2.2% |
| 1Y | 5.2% | 15.8% | 13.3% |
Return vs Industry: MYE0 underperformed the German Life Sciences industry which returned 15.9% over the past year.
Return vs Market: MYE0 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| MYE0 volatility | |
|---|---|
| MYE0 Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MYE0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MYE0's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MYE0 fundamental statistics | |
|---|---|
| Market cap | €361.33m |
| Earnings (TTM) | -€32.57m |
| Revenue (TTM) | €41.78m |
8.6x
P/S Ratio-11.1x
P/E RatioIs MYE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYE0 income statement (TTM) | |
|---|---|
| Revenue | US$45.44m |
| Cost of Revenue | US$5.26m |
| Gross Profit | US$40.18m |
| Other Expenses | US$75.61m |
| Earnings | -US$35.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 88.43% |
| Net Profit Margin | -77.97% |
| Debt/Equity Ratio | 0% |
How did MYE0 perform over the long term?
See historical performance and comparison